We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Intravacc to In-license CimCure’s iBoost Technology
Product News

Intravacc to In-license CimCure’s iBoost Technology

Intravacc to In-license CimCure’s iBoost Technology
Product News

Intravacc to In-license CimCure’s iBoost Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Intravacc to In-license CimCure’s iBoost Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Netherlands based Intravacc, a translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines, has announced the signing of a strategic partnership agreement with Dutch-based CimCure, focusing on cancer immunotherapies for solid tumors, for in-licensing CimCure’s iBoost technology. This agreement offers Intravacc access to this technology in developing new vaccines and for providing services involving the in-licensed technique in mutually agreed countries. This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

The iBoost (immune boost) technology was developed at Amsterdam UMC, lab-location VUMC, by Prof. Dr. Arjan Griffioen, professor of experimental oncology and CSO at CimCure. This technology overcomes limitations over current methods for inducing antibody responses against cancer-specific antigens. iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance. This treatment strategy has long-term efficacy and is extremely cost-effective. Proof-of-concept has been shown in several preclinical models.

By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine. CimCure/Amsterdam UMC received a 1.3 million euro grant from Health Holland, an investment organization of the Ministry of Economic Affairs. In the collaboration, CimCure will focus on the design and preclinical validation of three different types of COVID-19 vaccine concepts, while Intravacc will be responsible for the vaccine process development, the pilot production of the candidate vaccine under GMP conditions and for a phase I clinical trial.


Advertisement